UNSPSC 51383904: Nifenazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H16N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8780F0K71U, chemically known as 2,3-dimethyl-4-nicotinamido-1-phenyl-3-pyrazolin-5-on but generally known as nifenazone, which bears US NIH Compound Identifier 4487. European Medicines Agency schedules Nifenazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09256MIG. The term NIFENAZONE is an International Non-Proprietary Name.

UNSPSC 51383904 Nifenazone is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent opportunities show that state and local jurisdictions are buying naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products under related pharmaceutical purchasing programs rather than nifenazone specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering MMCAP on behalf of participating state and local facilities across multiple states including Oregon). Work being solicited ranges from direct procurement of finished pharmaceutical and OTC products for community health initiatives to vendor capacity assessments for direct-to-manufacturer prescription programs and bulk generic pharmaceutical supply agreements distributed through authorized wholesalers.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and specific insurance coverage. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor information on direct-to-manufacturer prescription programs and vendor capacity for negotiated net pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement.